Corgentech Reports Phase 2 Trial Results For 4975 In Hernia Repair Pain

... CorgentechInc. (Nasdaq: CGTK) today reported clinical results from a Phase 2 trial of4975, the company''s novel, long-acting, non-opioid drug candidate beingdeveloped in multiple mid-stage clinical trials for site-specific, moderate tosevere pain. The 41-patient, randomized, double-blind, parallel-group, placebo-controlled European study was designed to measure the effectiveness of 4975 intreating pain induced by surgical repair of an inguinal (groin) hernia asmeasured one and four weeks after surgery... click link for more info. ...